Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type i interferon-mediated mechanism

Stroke

Volumn 43, Issue 5, 2012, Pages 1383-1389

  Leung, Philberta Y ^a   Stevens, Susan L ^a   Packard, Amy E B ^a   Lessov, Nikola S ^a   Yang, Tao ^b   Conrad, Valerie K ^a   Van Den Dungen, Noortje N A M ^a   Simon, Roger P ^b   Stenzel Poore, Mary P ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemia; Neuroprotection

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GARDIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SODIUM CHLORIDE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FUNCTIONAL STATUS; GENE INDUCTION; ISCHEMIC PRECONDITIONING; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AMINOQUINOLINES; ANIMALS; BRAIN; BRAIN INFARCTION; IMIDAZOLES; INTERFERON REGULATORY FACTOR-7; ISCHEMIC PRECONDITIONING; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; NEUROPROTECTIVE AGENTS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STROKE; TOLL-LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860216398     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.641522     Document Type: Article

References (30)

1. Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Biochem Biophys Res Commun. 2007;353:509-514. (Pubitemid 46023466)
2. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol. 2007;190:28-33. (Pubitemid 47625604)
3. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA. 2007;104:13798-13803. (Pubitemid 350003400)
4. Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke. 2008;39: 1314-1320. (Pubitemid 351440707)
5. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation. 2007;115:1599-1608. (Pubitemid 46648645)
6. Brea D, Blanco M, Ramos-Cabrer P, Moldes O, Arias S, Perez-Mato M, et al. Toll-like receptors 2 and 4 in ischemic stroke: Outcome and therapeutic values. J Cereb Blood Flow Metab. 2011;31-1424-1431.
7. Broad A, Kirby JA, Jones DE, Applied Immunology and Transplantation Research Group. Toll-like receptor interactions: Tolerance of myd88-dependent cytokines but enhancement of Myd88-independent interferon-beta production. Immunology. 2007;120:103-111.
8. Hosomi N, Ban CR, Naya T, Takahashi T, Guo P, Song XY, et al. Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:959-967. (Pubitemid 41061711)
9. Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158:995-1006.
10. Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, et al. Endotoxin preconditioning protects against the cytotoxic effects of tnfalpha after stroke: A novel role for tnfalpha in lps-ischemic tolerance. J Cereb Blood Flow & Metab. 2007;27:1663-1674. (Pubitemid 47476093)
11. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, et al. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: A critical role for IRF3. J Neurosci. 2009;29:9839-9849.
12. Veldhuis WB, Derksen JW, Floris S, van der Meide PH, de Vries HE, Schepers J, et al. Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. J Cereb Blood Flow Metab. 2003;23:1029-1039. (Pubitemid 37082428)
13. Liu H, Xin L, Chan BP, Teoh R, Tang BL, Tan YH. Interferon-beta administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neurosci Lett. 2002;327:146-148. (Pubitemid 34722428)
14. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, et al. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol. 2008;199:75-82.
15. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res. 1997;748:267-270. (Pubitemid 27094913)
16. Hickey EJ, You X, Kaimaktchiev V, Stenzel-Poore M, Ungerleider RM. Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2007;133:1588-1596. (Pubitemid 46802584)
17. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning prevents the cellular inflammatory response during ischemic neuroprotection in mice. Stroke. 2004;35:2576-2581. (Pubitemid 39458420)
18. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, et al. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2008;28:1040-1047. (Pubitemid 351589642)
19. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, et al. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci. 2011;31:8456-8463.
20. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206:1589-1602.
21. Clark WM, Lessov NS, Dixon MP, Eckenstein F. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol Res. 1997;19:641-648. (Pubitemid 28006649)
22. Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, et al. A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods. 2002;117:207-214. (Pubitemid 34721338)
23. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD. Chronic behavioral testing after focal ischemia in the mouse: Functional recovery and the effects of gender. Exp Neurol. 2004;187:94-104. (Pubitemid 38470016)
24. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7-and TLR8-independent fashion. J Invest Dermatol. 2006;126: 1338-1347. (Pubitemid 43997917)
25. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994;55:234-240. (Pubitemid 24066348)
26. Vartanian KB, Stevens SL, Marsh B, Williams-Karnesky RL, Lessov NS, Stenzel-Poore MP. LPS preconditioning redirects TLR signaling following stroke: Trif-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J Neuroinflammation. 2011;8:140.
27. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol. 2007;178: 1164-1171. (Pubitemid 46095190)
28. Yang H, Ma G, Lin CH, Orr M, Wathelet MG. Mechanism for transcriptional synergy between interferon regulatory factor (IRF)-3 and IRF-7 in activation of the interferon-beta gene promoter. Eur J Biochem. 2004; 271:3693-3703. (Pubitemid 39233612)
29. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLRdependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005;174:1932-1937. (Pubitemid 40223933)
30. Wang J, Campbell IL, Zhang H. Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry. 2008;13:293-301. (Pubitemid 351272648)